menu search

Richemont shareholder bluebell says company response strengthens its cases for board seat

Bluebell Capital Partners still wants a seat on the board of Richemont after the luxury group called on shareholders to reject its ...

August 8, 2022, 5:35 am

Valneva: vaccine business, catalysts ahead, and pfizer's lyme love

Valneva is a specialty vaccines company with an ongoing travelers vaccine business. Two major catalysts are around the corner: a BLA for chikungunya v...

August 8, 2022, 1:59 am

Poseida therapeutics: even after recent partnership, additional upside possible

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these ...

August 3, 2022, 3:09 pm

Wells fargo reinstates diverse slate hiring policy following june pause

Wells Fargo reinstated a hiring policy that requires recruiters to interview a diverse pool of candidat...

August 1, 2022, 3:38 pm

Is beyond meat the next big short squeeze candidate?

Beyond Meat could have the juice for the next big squeeze....

July 31, 2022, 6:50 am

Intellia therapeutics is pushing crispr-based therapy forward, slowly but surely

Recent data from Intellia's Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing ...

July 30, 2022, 1:31 am

Noble initiates coverage on eskay mining with an outperform rating, calling it a promising acquisition candidate in the golden triangle

Noble Capital Partners have initiated coverage on Eskay Mining Corp (TSX-V:ESK, OTCQX:ESKYF) with an Outperform rating and $2.25 target price. Eskay M...

July 27, 2022, 12:16 pm

Pacific biosciences: a prime candidate for my 'bio boom' portfolio

Pacific Biosciences of California "PacBio" is a prime candidate for the "Bio Boom" Portfolio in my Comp...

July 27, 2022, 2:40 am

Why shares of pagaya exploded higher again today

The company appears to be trading like a meme stock and short-squeeze candidate....

July 26, 2022, 3:15 pm

Olema (olma) up on fda fast track tag for breast cancer drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the t...

July 22, 2022, 8:35 am

Beyond meat, canoo, veru and more: 12 short squeeze candidates to watch

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze ...

July 20, 2022, 10:32 am

A quick look at lineage cell therapeutics and its product development efforts

Lineage Cell Therapeutics uses embryonic stem cells to develop cellular based drug therapies. The company's primary drug ...

July 20, 2022, 12:08 am

Why ncr stock jumped on tuesday

A private-equity firm may be courting NCR as a potential buyout candidate, but there may be a lot of le...

July 19, 2022, 3:49 pm

Acadia (acad) files an nda for its rett syndrome candidate

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older....

July 19, 2022, 1:09 pm

Celyad: probably still top-notch in oncology

Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four mon...

July 19, 2022, 8:30 am

Sesen bio pauses clinical development of its lead bladder cancer candidate in us

Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, ...

July 18, 2022, 8:35 am

Rolls-royce and bae to see increased defence spending whoever wins tory election

Increased spending on UK defence is unlikely to be affected by whoever wins the Tory party election race, according to analysts at US bank Citi. “We...

July 14, 2022, 9:47 am

Moderna (mrna) announces first participant in phase 1 trial of nipah virus vaccine mrna-1215

Moderna, Inc. (NASDAQ: MRNA) announced the first participant has been dosed in a Phase 1 trial of its Nipah virus (NiV) vaccine ...

July 12, 2022, 6:34 pm

Aldeyra's reproxalap hits primary goals in dry eye disease chamber crossover trial

Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an in...

July 12, 2022, 9:03 am

Moderna says one of its covid-19 booster candidates better protects against ba.4 and ba.5

Moderna Inc. MRNA, +2.22% said Monday that a bivalent COVID-19 booster that equally protects against BA.1 and the original strain of the virus produce...

July 11, 2022, 8:19 am


Search within

Pages Search Results: